CA4 and cancer: These preliminary investigations suggest that cis-restricted triazole analogues 3i, 3j, 3n, and 3r, in particular, could serve as promising alternatives to the original CA-4, although further studies about their biological activity are essential in order to fully determine their viability as therapeutic agents in the treatment of cancer.